Reference - Detail
| RRC ID | 42762 |
|---|---|
| Author | Wang H, Satoh M, Abe H, Sunamura M, Moriya T, Ishidoya S, Saito S, Hamada H, Arai Y. |
| Title | Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model. |
| Journal | Urology |
| Abstract |
OBJECTIVES:To investigate the therapeutic effect of AxdAdB-3, a double-restricted oncolytic adenovirus harboring a mutant E1A and an E1B-55KD deletion, on human bladder cancer cell lines and the SCID mouse model of orthotopic bladder cancer. METHODS:The cytopathic effects of AxdAdB-3 were evaluated in several cell lines (YTS-1, YTS-3, T24, J82, 5637) derived from human bladder or ureteral cancer and in a normal bladder mucosa-derived cell line (HCV29) with AxCAlacZ (control) or AxE1AdB (E1B-55KD-defective adenovirus) or dl922-947 (E1A-mutated adenovirus). The efficacy of bladder instillation therapy with AxdAdB-3 for orthotopic bladder cancer of SCID mice was investigated. The oncolytic effects were monitored by ultrasound examination. RESULTS:AxdAdB-3 caused the oncolysis of bladder cancer cell lines in vitro, and it was more cytopathic than AxE1AdB or dl922-947 in the cancer cell lines. AxdAdB-3 was not cytotoxic against HCV29. Direct instillation of AxdAdB-3 into the bladder of the orthotopic model inhibited tumor growth, leading to significantly prolonged survival. CONCLUSIONS:Oncolytic viral therapy delivered by instillation of AxdAdB-3 is a promising tool for treating bladder cancer. |
| Volume | 68(3) |
| Pages | 674-81 |
| Published | 2006-9-1 |
| DOI | 10.1016/j.urology.2006.04.021 |
| PII | S0090-4295(06)00612-1 |
| PMID | 16979729 |
| MeSH | Adenoviridae / genetics* Administration, Intravesical Animals Cell Line, Tumor Disease Models, Animal Humans Mice Mice, SCID Oncolytic Virotherapy / methods* Urinary Bladder Neoplasms / drug therapy* |
| IF | 1.924 |
| Times Cited | 14 |
| WOS Category | UROLOGY & NEPHROLOGY |
| Resource | |
| Human and Animal Cells | WI-38 |